A5063839083- Stress Responses and Cortisol
- Neuroscience and Neuropharmacology Research
- Tryptophan and brain disorders
- Neurogenesis and neuroplasticity mechanisms
- Treatment of Major Depression
- Neurotransmitter Receptor Influence on Behavior
- Receptor Mechanisms and Signaling
- Neuroendocrine regulation and behavior
- Nerve injury and regeneration
- Memory and Neural Mechanisms
- Nicotinic Acetylcholine Receptors Study
- Neuropeptides and Animal Physiology
- Health, Environment, Cognitive Aging
- Circadian rhythm and melatonin
- Nuclear Receptors and Signaling
- Functional Brain Connectivity Studies
- Diet and metabolism studies
- Mental Health Research Topics
- Pain Mechanisms and Treatments
- Complementary and Alternative Medicine Studies
- Electroconvulsive Therapy Studies
- Anesthesia and Neurotoxicity Research
- Mast cells and histamine
- Wnt/β-catenin signaling in development and cancer
- Bioinformatics and Genomic Networks
Inserm
2015-2024
Centre de recherche en Epidémiologie et Santé des Populations
2016-2024
Université Paris-Saclay
2016-2024
Université Paris-Sud
2011-2020
Cooperativa de Ensino Superior Politécnico e Universitário
2019
Institut Galien Paris-Saclay
2007-2016
University of Pittsburgh
2010-2013
Johns Hopkins University
2012
National Institutes of Health
2012
Université Paris Cité
2010
Objective The subgenual anterior cingulate cortex is implicated in the pathology and treatment response of major depressive disorder. Low levels brain-derived neurotrophic factor (BDNF) reduced markers for GABA function, including amygdala, are reported depression, but their contribution to dysfunction not known. Method Using polymerase chain reaction, we first assessed degree which BDNF controls mRNA expression (defined as dependency) 15 genes relating neuropeptide functions mice with...
Cognitive disturbances are often reported as serious incapacitating symptoms by patients suffering from major depressive disorders (MDDs). Such deficits have been observed in various animal models based on environmental stress. Here, we performed a complete characterization of cognitive functions neuroendocrine mouse model depression chronic (4 weeks) corticosterone administration (CORT). performances were assessed using behavioral tests measuring episodic (novel object recognition test,...
Agomelatine (S20098) is a novel antidepressant drug with melatonergic agonist and 5-HT2C receptor antagonist properties, displaying antidepressant/anxiolytic-like properties in animal models humans. In depression/anxiety-like mouse model which the response of HPA axis blunted, we investigated whether agomelatine could reverse behavioural deficits related to depression/anxiety compared classical selective serotonin reuptake inhibitor, fluoxetine. Adult mice were treated for 8 wk either...
Vortioxetine (Lu AA21004) is an investigational novel antidepressant with multimodal activity that functions as a 5-HT3, 5-HT7 and 5-HT(1D) receptor antagonist, 5-HT(1B) partial agonist, 5-HT(1A) agonist inhibitor of the 5-HT transporter in vitro. Here we explore its anxiolytic potential adult mice. was assessed BalB/cJ@RJ mice using open-field forced-swim tests (acute: p.o. 1 h, repeated: daily 21 days), 129S6/SvEvTac novelty suppressed feeding paradigm sustained: 14 or days). Fluoxetine...
Numerous clinical reports underscore the frequency of olfactory impairments in patients suffering from major depressive disorders (MDDs), yet underlying physiopathological mechanisms remain poorly understood. We hypothesized that one key link between deficits and MDD lies hypercortisolemia, a cardinal symptom MDD. Corticosterone (CORT) is known to negatively correlate with hippocampal neurogenesis, its effects on neurogenesis olfaction unknown. Here we used rodent model...
In the last decades, few mechanistically novel therapeutic agents have been developed to treat mental and neurodegenerative disorders. Numerous studies suggest that targeting BDNF its TrkB receptor could be a promising strategy for treatment of brain However, development potent small ligands has proven difficult. By using peptidomimetic approach, we highly selective inhibitor, cyclotraxin-B, capable altering TrkB-dependent molecular physiological processes such as synaptic plasticity,...
Genome-wide expression and genotyping technologies have uncovered the genetic bases of complex diseases at unprecedented rates. However, despite its heavy burden high prevalence, molecular characterization major depressive disorder (MDD) has lagged behind. Transcriptome studies report multiple brain disturbances but are limited by small sample sizes. association (GWAS) weak results suggest an overlapping risk with other neuropsychiatric disorders. We performed a systematic altered function...
GPR88, an orphan G protein-coupled receptor, was designated Strg/GPR88 for striatum-specific receptor (K. Mizushima et al. (2000)Genomics, 69, 314-321). In this study, we focused on striatal GPR88 protein localization using a polyclonal antibody. We established that the distribution of immunoreactivity in rat brain matched transcripts and provided evidence its exclusive neuronal expression. is abundant throughout striatum primate, with expression limited to two subsets projection medium...
Understanding the pathophysiology of affective disorders and their treatment relies on availability experimental models that mimic aspects disease. Most studies depressive are conducted with male rodents, mostly because including females in protocols is more difficult. Indeed, there a complex series changes brain due to estrous cycle, adding an important variability factor However, twice as many women men have lifetime diagnosis major disorder (MDD), so we need develop reliable female...
Glutamatergic dysfunctions are observed in the pathophysiology of depression. The glutamatergic synapse as well AMPA receptor's (AMPAR) activation may represent new potential targets for therapeutic intervention context major depressive disorders. S 47445 is a novel AMPARs positive allosteric modulator (AMPA-PAM) possessing procognitive, neurotrophic properties and enhancing synaptic plasticity. Here, we investigated antidepressant/anxiolytic-like effects mouse model anxiety/depression based...
Abstract Substance P antagonists of the neurokinin-1 receptor type (NK1) are gaining growing interest as new antidepressant therapies. It has been postulated that these drugs exert this putative therapeutic effect without direct interactions with serotonin (5-HT) neurones. Our recent microdialysis experiment performed in NK1 knockout mice suggested evidence changes 5-HT neuronal function (Froger et al. 2001). The aim present study was to evaluate effects coadministration selective reuptake...